Today news
The same in other media
Dabur to conduct clinical study to assess if Chyawanprash can prevent covid-19
Reading now: 237
NEW DELHI: India’s largest ayurvedic consumer goods firm Dabur India has launched clinical trials to assess whether its flagship product Chyawanprash can boost immunity against the covid-19.
The open-label, randomised trial, which will be conducted at five sites across India over 6-8 months, will see whether Chyawanprash can prevent the fatal respiratory disease or reduce the severity of it, according to information provided by the Union government’s clinical trial registry.
From the five Ayurvedic hospitals included as sites for the trial, the company has so far received approval for the ethics committee of the National Institute of Ayurveda in Jaipur, Parul Ayurveda Hospital in Vadodara and Sumatibhai Shah Ayurved Mahavidyalaya in Pune,
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
COVID-19
United States
|
Cases: 46 252 513
Deaths: 750 423
Recovered: 0
|
India
|
Cases: 34 321 025
Deaths: 459 652
Recovered: 0
|
Brazil
|
Cases: 21 835 785
Deaths: 608 235
Recovered: 0
|
United Kingdom
|
Cases: 9 215 683
Deaths: 141 607
Recovered: 0
|
Russia
|
Cases: 8 494 589
Deaths: 237 619
Recovered: 0
|